A Study to Compare Bioequivalence Approach Between FDA and EMA in a Highly Variable Drug: Pinaverium Bromide Film Tablets
- 15 August 2022
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (11) , 3149-3154
Abstract
No abstract availableKeywords
Funding Information
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (3160736)
This publication has 12 references indexed in Scilit:
- Pinaverium Reduces Symptoms of Irritable Bowel Syndrome in a Multicenter, Randomized, Controlled TrialClinical Gastroenterology and Hepatology, 2015
- Role of antispasmodics in the treatment of irritable bowel syndromeWorld Journal of Gastroenterology, 2014
- Intestinal Targeting of Drugs: Rational Design Approaches and ChallengesCurrent Topics in Medicinal Chemistry, 2013
- Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug AdministrationThe AAPS Journal, 2012
- A sensitive and specific liquid chromatography/tandem mass spectrometry method for determination of pinaverium bromide in human plasma: application to a pharmacokinetic study in healthy volunteersBiomedical Chromatography, 2011
- Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug ApplicationsThe AAPS Journal, 2008
- Effects of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patientsBiomedicine & Pharmacotherapy, 2000
- Effect of pinaverium bromide on jejunal motility and colonic transit time in healthy humansBiomedicine & Pharmacotherapy, 1992
- Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disordersGeneral Pharmacology: The Vascular System, 1990
- Pinaverium bromide: A calcium channel blocker acting selectively on the gastrointestinal tractDrug Development Research, 1989